FDA medical oncologists discuss the December 20, 2017, approval of nivolumab for the adjuvant treatment of patients with melanoma.

FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Science

Share FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

Sign up to save your podcasts

FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma

FDA D.I.S.C.O.: Nivolumab for adjuvant treatment of patients with melanoma